Novavax
Sanofi inks US$1.2 billion vaccine licensing deal with Novavax
The pact links two big players in the vaccine world that both missed out on the rush to develop and commercialise Covid shots quickly during the pandemic
Novavax to cut 12% of its global workforce
Vaccine maker Novavax said on Wednesday (Jan 31) it will reduce its total global workforce by about 12 per cent as part of its ongoing efforts to reduce costs.
Novavax lays off 25% of workforce, releases 2023 outlook
NOVAVAX said on Tuesday (May 9) it will reduce its global workforce by 25 per cent as the cash-strapped biotech pushes forward with its plans to slash expenses and navigate tepid demand for its Covid-...
Novavax tumbles on cut to UK Covid vaccine-supply deal, capital raising
Novavax shares fell the most in almost four years on Thursday (Dec 15) after the company announced it had cut its vaccine supply to the UK and was seeking additional equity and debt.
FDA experts weigh authorising Novavax Covid-19 vaccine in US
A panel of experts convened by the US drug regulator was meeting on Tuesday (Jun 7) to consider authorizing the Novavax Covid-19 shot, a late runner in the fight against the virus that could nonethele...
Novavax plunges on ‘harsh’ FDA review ahead of Tuesday panel
NOVAVAX slumped 20 per cent on Friday (Jun 4) after US regulators raised concerns over the biotech’s much-anticipated Covid-19 vaccine.
Japan's Takeda forecasts rebound despite full-year profit drop
JAPAN'S Takeda Pharmaceutical said on Wednesday (May 11) its 12-month operating profit slid 9.5 per cent, although the country's largest drugmaker forecast a rebound for the current year.
